Tvardi Therapeutics Completes Merger with Cara Therapeutics, Secures Funding Through 2026

Reuters05-14

Tvardi <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Completes Merger with <a href="https://laohu8.com/S/CARA">Cara Therapeutics</a>, Secures Funding Through 2026

Tvardi Therapeutics Inc., a clinical-stage biopharmaceutical company, has successfully completed its merger with Cara Therapeutics. As a result of the transaction, Tvardi received approximately $23.8 million in net cash from Cara, enhancing its financial position. This merger, combined with a previous private placement financing of $28.3 million, strengthens Tvardi's capability to fund its operations. The company now anticipates having sufficient resources to sustain its activities into the second half of 2026. The merger is expected to heighten Tvardi's visibility and access to capital, propelling its development programs, including those targeting idiopathic pulmonary fibrosis and hepatocellular carcinoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-047856), on May 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2535608296?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 04:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535608296","market":"us","top_or_hot":-1,"title":"Tvardi Therapeutics Completes Merger with Cara Therapeutics, Secures Funding Through 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Completes Merger with <a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a>, Secures Funding Through 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TVRD\">Tvardi Therapeutics Inc</a>., a clinical-stage biopharmaceutical company, has successfully completed its merger with Cara Therapeutics. As a result of the transaction, Tvardi received approximately $23.8 million in net cash from Cara, enhancing its financial position. This merger, combined with a previous private placement financing of $28.3 million, strengthens Tvardi's capability to fund its operations. The company now anticipates having sufficient resources to sustain its activities into the second half of 2026. The merger is expected to heighten Tvardi's visibility and access to capital, propelling its development programs, including those targeting idiopathic pulmonary fibrosis and hepatocellular carcinoma.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-047856), on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tvardi Therapeutics Completes Merger with Cara Therapeutics, Secures Funding Through 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTvardi Therapeutics Completes Merger with Cara Therapeutics, Secures Funding Through 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-14 04:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Completes Merger with <a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a>, Secures Funding Through 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TVRD\">Tvardi Therapeutics Inc</a>., a clinical-stage biopharmaceutical company, has successfully completed its merger with Cara Therapeutics. As a result of the transaction, Tvardi received approximately $23.8 million in net cash from Cara, enhancing its financial position. This merger, combined with a previous private placement financing of $28.3 million, strengthens Tvardi's capability to fund its operations. The company now anticipates having sufficient resources to sustain its activities into the second half of 2026. The merger is expected to heighten Tvardi's visibility and access to capital, propelling its development programs, including those targeting idiopathic pulmonary fibrosis and hepatocellular carcinoma.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-047856), on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVRD","symbol_name":"Tvardi Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDLbd06Bh:1","article_id":"2535608296","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535608296","pubTimestamp":1747168062,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tvardi Therapeutics Inc., a clinical-stage biopharmaceutical company, has successfully completed its merger with Cara Therapeutics. As a result of the transaction, Tvardi received approximately $23.8 million in net cash from Cara, enhancing its financial position. This merger, combined with a previous private placement financing of $28.3 million, strengthens Tvardi's capability to fund its operations. The company now anticipates having sufficient resources to sustain its activities into the second half of 2026. The merger is expected to heighten Tvardi's visibility and access to capital, propelling its development programs, including those targeting idiopathic pulmonary fibrosis and hepatocellular carcinoma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVRD":"Tvardi Therapeutics Inc","BK4007":"制药","CARA":"Cara Therapeutics"},"translate_title":"Tvardi Therapeutics完成与Cara Therapeutics的合并，确保2026年之前的资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVRD":0.9,"CARA":0.9},"content_text":"Tvardi Therapeutics Completes Merger with Cara Therapeutics, Secures Funding Through 2026\n    \n\nTvardi Therapeutics Inc., a clinical-stage biopharmaceutical company, has successfully completed its merger with Cara Therapeutics. As a result of the transaction, Tvardi received approximately $23.8 million in net cash from Cara, enhancing its financial position. This merger, combined with a previous private placement financing of $28.3 million, strengthens Tvardi's capability to fund its operations. The company now anticipates having sufficient resources to sustain its activities into the second half of 2026. The merger is expected to heighten Tvardi's visibility and access to capital, propelling its development programs, including those targeting idiopathic pulmonary fibrosis and hepatocellular carcinoma.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-047856), on May 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2535608296","isCrawlerRequest":true}